Ph.D., Cornell University Graduate School of Medical Sciences, 1991
M.D., Cornell University Medical College, 1992
|With joint appointments at CSHL and Northwell Health, I am working to expand clinical cancer research at our institutions to provide new treatments for patients as well as greater insight into the biology of this complex set of diseases. In my own research, I am collaborating on research in soft-tissue and bone sarcomas to better understand the cancer microenvironment and epigenetics, targeting molecular weaknesses to halt cancer growth.|
Robert Maki is interested in applying basic research discoveries in the clinic to treat patients with sarcomas and other neoplasms of soft-tissue and bone. Connective tissue represents a remarkable diversity of tissues. Pathologists recognize more than 70 types of sarcoma, but using molecular characteristics (changes in DNA sequence like translocations or mutations) there are even more subtypes of sarcomas. Dr. Maki is working to exploit these molecular changes to inhibit growth and proliferation of sarcoma.
Dr. Maki also maintains a particular interest in angiosarcoma, leiomyosarcoma and desmoid tumors as manifestations of the interplay of the microenvironment with cancer. He is also exploring the common pathways in metabolism and epigenetics in the hope that they may provide useful tools to circumvent the well-appreciated genetic heterogeneity of most cancers.
In developing the Center for New Cancer Therapies (CNCT) at Northwell Health Cancer Institute, Dr. Maki is facilitating the translation of basic research at CSHL into the clinics of partner institutions, in particular Northwell Health’s Monter Cancer Center. The CNCT will help to inform and advance basic research by bringing patient samples and data back into the laboratories at CSHL. Dr. Maki brings significant expertise in the interplay between clinical and basic research: he has written and conducted phase I-II-III trials in soft tissue and bone tumors at his home institutions and via collaborative efforts such as SARC (Sarcoma Alliance for Research through Collaboration), and will apply that knowledge as CSHL and Northwell Health expand their clinical trials.
Gronchi, A. and Maki, R. G. and Jones, R. L. (2017) Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncol 13(1s) pp. 13-21.
Lee, C. K. and Goldstein, D. and Gibbs, E. and Joensuu, H. and Zalcberg, J. and Verweij, J. and Casali, P. G. and Maki, R. G. and Cioffi, A. and McArthur, G. and Lord, S. J. and Yip, D. and Kanjanapan, Y. and Rutkowski, P. (2015) Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. Eur J Cancer 51(7) pp. 852-60.
Brohl, A. S. and Li, L. and Andikyan, V. and Obican, S. G. and Cioffi, A. and Hao, K. and Dudley, J. T. and Ascher-Walsh, C. and Kasarskis, A. and Maki, R. G. (2015) Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist 20(4) pp. 433-9.
Palmerini, E. and Staals, E. L. and Maki, R. G. and Pengo, S. and Cioffi, A. and Gambarotti, M. and Picci, P. and Daolio, P. A. and Parafioriti, A. and Morris, C. and Antonescu, C. R. and Gronchi, A. and Casali, P. G. and Donati, D. M. and Ferrari, S. and Stacchiotti, S. (2015) Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer 51(2) pp. 210-7.
Dickson, M. A. and D'Adamo, D. R. and Keohan, M. L. and D'Angelo, S. P. and Carvajal, R. D. and Gounder, M. M. and Maki, R. G. and Qin, L. X. and Lefkowitz, R. A. and McKennon, O. R. and Hirst, C. M. and Schwartz, G. K. and Tap, W. D. (2015) Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma 2015pp. 532478.Additional materials of the author at
CSHL Institutional Repository
2014 Fellow, American College of Physicians
2014 Life Raft Group (GIST), Clinician of the Year
2013 Nobility in Science Award, Sarcoma Foundation of America
2009 NCI Clinical Investigator Team Leadership Award
2007 Byrne Fund Award, Memorial Sloan-Kettering Cancer Center